康宁杰瑞制药-B：截至2024年12月31日止年度年度业绩公告

ALPHAMAB ONCOLOGY 9966 20241231 2024123120231231 •20241KN035(MSI-H)(dMMR) •20241GlenmarkSpecialty S.A.GlenmarkGlenmarkKN035KN035 •20242KN046BCII(PFS)OSNature Communications •202432024202416 •2 0 2 43K N 0 4 6NSCLCIICell Reports Medicine•20243JSKN0332HER2I/II•20243JSKN016CDE•20244JSKN003HER2IJSKN003•20245JSKN016I•20246JSKN003I/IIIJSKN003•20246ArriVent BioPharma, Inc.(Alphatecan)ADC•20248KN035CDE(TMB-H)•20248KN046IbCancer Immunology, Immunotherapy•20249KN035202412 •20249KN046sqNSCLCIIIOS •20249JSKN003PROCHER2HER2+(IHC3+)BCESMO•2024930.8JSKN003•202410KN026HER2+BCIIICDEHER2+GCGEJHER2+BCIII•202411JSKN033HER2I/II2024•202411E20241002024TOP5•2024112024(CHTV)2024TOP 100•202412KN046NSCLCII2024ESMOKN046NSCLC•202412JSKN003CDEIIIHER2BCIIIII•202412JSKN033I/IIINDCDE •20251KN026HER2+BCIICancer Communications •20251JSKN033I/II •20252CDEJSKN003HER2+ BCIIIJSKN003(T-DM1)HER2+BC •20252JSKN003III •20252KN046IINature Communications •20253JSKN003CDEHER2 •20253JSKN016(TKI)NSCLCINDCDEJSKN016 NSCLCII •20253JSKN016HER2+ BCINDCDEJSKN016HER2+ BC •20253KN026KN046BCHER2+IISignal Transduction and Targeted Therapy ADC ADCIII 1. (i)sdAb(ii)sdAbCRIB(iii)FDA40,000LADC 18A.08(3) ADC 20241231640.120231231218.82024123160.32023123155.22024123162.02023123191.82024123113.22023123133.120241231166.320231231211.420241231404.220231231407.52024123174.62023123179.3202412319.92023123112.2 20241231640.120231231218.8(i)(ii)(iii)(iv) 123120242023 20241231159.520231231195.620162KN03520241231KN035122.520231231128.42024123137.0202367.2202112KN035 20241231464.220237.22024123120241252024652024929 20241231KN0351.920230.9202111KN035 202412314.220230.4 2024123110.3202314.7 2024123160.3202355.256.0202351.34.320233.920241231 2024123129.862.02023123191.82023123174.02024123149.32023123117.82024123112.8 2024123113.22023123133.1 (i)(ii)(iii)(iv)(v) 20241231404.220231231407.5 2024123174.62023123179.3 (i)(ii)(iii) 2023123112.2202412319.9(i)(ii) 202412313,489.1202312313,315.6 202320241231 20241231166.320231231210.6 20231231550.150.120241231500.0 16 2023123126.92.92024123124.0 2024123181.82023123178.7 2024123116.5202312317.12024 202412313.82023 (i)(ii)(iii) 2023123166.526.92024123139.6 (i)(ii) 202312311,086.0202412311,112.120231231321.220241231459.3 20241231180.820231231175.1 202312314.4202412313.1 202312317.1202412313.7 202312312024123125.540.12.67%4.35%20233.70%4.35% 20241231 202412312019122 2025 20241231182.220231231250.02.54%2.67%20241231235.620.2 (1)6.745.84(2)6.415.55(3)(0.51)(0.50) (1) (2)(3)100% 20241231 20241231 20241231235.620.2 20241231 202412312024123120241231 20241231420202343520241231175.920231231189.3 D.20204222024521 166,342(210,593)9 –– 10 166,342(210,593) (48)(794) 166,294(211,387) 0.17(0.22) 0.17(0.22) 20242023 121316 499,994550,05224,01726,9014,5745791,8211,051 14151617 254,044266,838 1,457,3051,291,692 1. 20183282019121220241231 2. 202411 161177 97971028 3 3 111324 2118 1220251132026114202711 3. 4. 638,207217,901 (i) 10% AiBii (i)2 0 2 41 23 1159,457,0002023195,551,0002023313,000 (ii)20241231383,965,00020237,202,0005,587,00020232,173,000 (ii) (a) • • (b) 30 (c) (d) 4560202330 5. 2,984,00020232,232,0009,784,000202315,543,000 6. 7. 8. 9. 25%202325%202210182022202415%[2018]76510 201726%Alphamab Australia26%202326% 28.25%216.5%16.5% 21% 10. 11. 20231231 12. 4.75%9.50%20%19%31.67% 2024123114,310,000202313,662,00010,906,000202310,067,000 3 i3,821,00020233,813,000ii20232,397,000202412319,565,00020234,580,0009,798,00020234,580,000 202320241231 14. 15. 20242023 16,5197,131 20231115,490,000 20242023 060 16,5197,131 20241231 17. 20242023 3,785– 45 20242023 19. 20242023 20. 20242023 iiiii (i)20231127,522,000(ii)(iii)2.67%4.35%20233.70%4.35% 21. 20242023 22. 202412312023 202412312023 201832820191212 C1 20241231C.2.1C.2.1 20241231 20241231 C3 571 2024815202461250.020248152,952,000 3.10(2)3.21 20241231• • •20241231•• 201912122,042.520241231 20241231202412 31 KN026 20232Rubymab15.2215.0525,000,00050376.220232316.142023232023292024123150.9 ADC 2025 20241231 2025612 20256920256122025612202566183171712-1716 (www.hkexnews.hk)(www.alphamabonc.com) D22024123120254 2025325